|
Subgroup analysis
|
OS
|
PFS
|
|---|
|
No. of studies
|
Pooled HR (95% CI)
|
P value
|
Heterogeneity
|
No. of studies
|
Pooled HR (95% CI)
|
P value
|
Heterogeneity
|
|---|
|
I2 (%)
|
P
|
I2 (%)
|
P
|
|---|
|
Overall
|
17
|
2.08 (1.78–2.45)
|
< 0.00001
|
8
|
0.36
|
8
|
1.51 (1.20–1.91)
|
0.0005
|
25
|
0.23
|
|
Type of PS scale
|
|
KPS
|
6
|
2.20 (1.65–2.94)
|
< 0.00001
|
24
|
0.26
|
5
|
1.74 (1.19–2.56)
|
0.005
|
0
|
0.50
|
|
ECOG PS
|
11
|
2.03 (1.68–2.46)
|
< 0.00001
|
6
|
0.39
|
3
|
1.39 (1.04–1.87)
|
0.03
|
61
|
0.08
|
|
Study setting
|
|
Asia
|
6
|
2.25 (1.71–2.95)
|
< 0.00001
|
26
|
0.24
|
4
|
1.73 (1.14–2.64)
|
0.01
|
11
|
0.34
|
|
Europe
|
8
|
1.95 (1.56–2.43)
|
< 0.00001
|
28
|
0.20
|
4
|
1.42 (1.08–1.88)
|
0.01
|
44
|
0.15
|
|
America
|
3
|
2.25 (1.43–3.53)
|
0.0005
|
0
|
0.93
|
0
|
–
|
–
|
–
|
–
|
|
Year of publication
|
|
Before 2015
|
11
|
1.79 (1.44–2.22)
|
< 0.00001
|
17
|
0.28
|
6
|
1.51 (1.18–1.94)
|
0.001
|
44
|
0.11
|
|
After 2015
|
6
|
2.49 (1.97–3.15)
|
< 0.00001
|
0
|
0.95
|
2
|
1.50 (0.73–3.07)
|
0.27
|
0
|
0.56
|
|
NOS score
|
|
6
|
5
|
2.07 (1.57–2.74)
|
< 0.00001
|
28
|
0.24
|
2
|
0.90 (0.54–1.50)
|
0.67
|
40
|
0.20
|
|
7
|
7
|
1.80 (1.40–2.32)
|
< 0.00001
|
19
|
0.29
|
4
|
1.57 (1.18–2.10)
|
0.002
|
0
|
0.92
|
|
8
|
5
|
2.61 (1.92–3.55)
|
< 0.00001
|
0
|
0.90
|
2
|
2.43 (1.36–4.33)
|
0.003
|
0
|
0.43
|
- OS overall survival, PFS progression-free survival, PS performance status, KPS Karnofsky performance status, ECOG PS Eastern Cooperative Oncology Group performance status, NOS Newcastle-Ottawa score, CI confidence interval
